@article{10.1172/jci.insight.157421, author = {Mansi Shah AND Harish Kumar AND Shaowei Qiu AND Hui Li AND Mason Harris AND Jianbo He AND Ajay Abraham AND David K. Crossman AND Andrew Paterson AND Robert S. Welner AND Ravi Bhatia}, journal = {JCI Insight}, publisher = {The American Society for Clinical Investigation}, title = {Low c-Kit expression identifies primitive, therapy-resistant CML stem cells}, year = {2023}, month = {1}, volume = {8}, url = {https://insight.jci.org/articles/view/157421}, abstract = {Despite the efficacy of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), malignant long-term hematopoietic stem cells (LT-HSCs) persist as a source of relapse. However, LT-HSCs are heterogenous and the most primitive, drug-resistant LT-HSC subpopulations are not well characterized. In normal hematopoiesis, self-renewal and long-term reconstitution capacity are enriched within LT-HSCs with low c-Kit expression (c-KITlo). Here, using a transgenic CML mouse model, we found that long-term engraftment and leukemogenic capacity were restricted to c-KITlo CML LT-HSCs. CML LT-HSCs demonstrated enhanced differentiation with expansion of mature progeny following exposure to the c-KIT ligand, stem cell factor (SCF). Conversely, SCF deletion led to depletion of normal LT-HSCs but increase in c-KITlo and total CML LT-HSCs with reduced generation of mature myeloid cells. CML c-KITlo LT-HSCs showed reduced cell cycling and expressed enhanced quiescence and inflammatory gene signatures. SCF administration led to enhanced depletion of CML primitive progenitors but not LT-HSCs after TKI treatment. Human CML LT-HSCs with low or absent c-KIT expression were markedly enriched after TKI treatment. We conclude that CML LT-HSCs expressing low c-KIT levels are enriched for primitive, quiescent, drug-resistant leukemia-initiating cells and represent a critical target for eliminating disease persistence.}, number = {1}, doi = {10.1172/jci.insight.157421}, url = {https://doi.org/10.1172/jci.insight.157421}, }